160 related articles for article (PubMed ID: 38423708)
41. Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China.
Gu D; Li J; Miao Y
Expert Opin Pharmacother; 2022 Dec; 23(18):1979-1986. PubMed ID: 36329558
[TBL] [Abstract][Full Text] [Related]
42. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
Chen SS; Barrientos JC; Ferrer G; King-Richards M; Chen YJ; Ravichandran P; Ibrahim M; Kieso Y; Waters S; Kutok JL; Peluso M; Sharma S; Weaver DT; Pachter JA; Rai KR; Chiorazzi N
Clin Cancer Res; 2023 May; 29(10):1984-1995. PubMed ID: 37071496
[TBL] [Abstract][Full Text] [Related]
43. Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report.
Lolli G; Casadei B; Pellegrini C; Argnani L; Cocito F; Zinzani PL
Tumori; 2021 Dec; 107(6):NP105-NP107. PubMed ID: 34167407
[TBL] [Abstract][Full Text] [Related]
44. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Davids MS; Fisher DC; Tyekucheva S; McDonough M; Hanna J; Lee B; Francoeur K; Montegaard J; Odejide O; Armand P; Arnason J; Brown JR
Leukemia; 2021 Apr; 35(4):1064-1072. PubMed ID: 32820271
[TBL] [Abstract][Full Text] [Related]
45. Idelalisib: first global approval.
Markham A
Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
[TBL] [Abstract][Full Text] [Related]
46. Ibrutinib in CLL/SLL: From bench to bedside (Review).
Zi F; Yu L; Shi Q; Tang A; Cheng J
Oncol Rep; 2019 Dec; 42(6):2213-2227. PubMed ID: 31638169
[TBL] [Abstract][Full Text] [Related]
47. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Skånland SS; Brown JR
Haematologica; 2023 Jan; 108(1):9-21. PubMed ID: 35899388
[TBL] [Abstract][Full Text] [Related]
48. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
49. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
[TBL] [Abstract][Full Text] [Related]
50. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
51. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
53. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Brown JR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):807-826. PubMed ID: 34174987
[TBL] [Abstract][Full Text] [Related]
54. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
55. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
[TBL] [Abstract][Full Text] [Related]
56. PI3K in CLL: are 2 isoforms better than 1?
Steele AJ
Blood; 2014 Dec; 124(24):3508-10. PubMed ID: 25477481
[No Abstract] [Full Text] [Related]
57. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.
Izutsu K; Kato K; Kiyoi H; Yamamoto G; Shimada K; Akashi K
Int J Hematol; 2020 Oct; 112(4):504-509. PubMed ID: 32613313
[TBL] [Abstract][Full Text] [Related]
58. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
[TBL] [Abstract][Full Text] [Related]
59. Oral oncolytic treatment for chronic lymphocytic leukemia.
Harris V; Borlagdan J; Muluneh B
J Oncol Pharm Pract; 2022 Jun; 28(4):935-944. PubMed ID: 35084245
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]